4699
Validation of the pharmacoeconomic model of emtricitabin/ rilpivirine/ tenofovir (eviplera) inclusion in highly active antiretroviral therapy of HIV/AIDS in the Russian Federation
The article deals with the results of validation of the pharmacoeconomic model of emtricitabin/ rilpivirine/ tenofovir (Eviplera) inclusion in highly active antiretroviral therapy of HIV/AIDS in the Russian Federation.
Скорее всего ваш браузер не поддерживает PDF и Adobe Reader, нажмите здесь, чтобы просмотреть PDF
Bibliography link:
Kulikov A.Y., Babiy V.V. Validation of the pharmacoeconomic model of emtricitabin/ rilpivirine/ tenofovir (eviplera) inclusion in highly active antiretroviral therapy of HIV/AIDS in the Russian Federation // Pharmacoeconomics: theory and practice. - 2015. - Vol.3, №2. - P.86-87 DOI: https://doi.org/10.30809/phe.2.2015.3
Comments0